PRF Technologies Ltd. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
PRFX Nasdaq 2834 www.painreform.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for PRF Technologies Ltd.

PRF Technologies’ GridFeed(TM) to Explore Strategic Growth Opportunity in AI Data Center Power Optimization - Sep 16th, 2026 7:00 am
PRF Technologies to Establish GridFeed™ as a Standalone Subsidiary to Pursue Strategic Alliances for Its AI-Driven Renewable Energy Trading Platform - Sep 9th, 2026 6:30 am
PRF Technologies Provides First Half 2026 Business Update Highlighting Significant Progress Across Healthcare and AI Energy Business - Sep 3rd, 2026 6:30 am
PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms - Jul 27th, 2026 6:30 am
PRF Technologies to Showcase GridFeed™ at Energy Trading Week Europe 2026 - Jul 21st, 2026 6:30 am
PRF Technologies Expands DeepSolar Predict™ Platform with Battery-to-Revenue Intelligence, Extending AI-Driven Revenue Optimization Across Solar and Energy Storage Assets - Jul 15th, 2026 7:15 am
PRF Technologies’ DeepSolar Successfully Validates Predict™ AI Platform for Renewable Energy Revenue Optimization Using Real-World European Market Data - Jul 8th, 2026 6:30 am
PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark - Jun 25th, 2026 6:30 am
Top Premarket Gainers - May 29th, 2026 5:16 am
PRF Technologies Advances DeepSolar Predict™ Toward Commercial Launch as AI Platform Targets Revenue Optimization Across Renewable Energy Markets - May 28th, 2026 6:30 am
PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study - May 26th, 2026 6:30 am
EXCLUSIVE: PRF Technologies Advances Drop-Less Drug For Cataract Surgery Pain - Apr 30th, 2026 8:31 pm
PRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical Trial - Apr 28th, 2026 6:00 am
PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms - Mar 27th, 2026 6:00 am
PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar’s Installed Commercial Base - Feb 11th, 2026 6:30 am
PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy - Jan 20th, 2026 7:05 am
PainReform Ltd. Changes Name to PRF Technologies Ltd. Reflecting Expansion into Diversified Healthcare and AI-Driven Energy Platforms - Jan 15th, 2026 2:05 pm
PainReform’s LayerBio’s Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies - Jan 12th, 2026 7:00 am